Across TCGA pan-cancer cohorts, SNORD114-12 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SNORD114-12 data layer compared with 11 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher SNORD114-12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNORD114-12 expression acts as an unfavorable survival marker.
SARC are the cancer types where SNORD114-12 Mutation most reproducibly stratifies survival.